Dr. Orgel is currently an attending physician on the Medical Supportive Care/Survivorship and Supportive Care Program and the Leukemia and Lymphoma Team within the Division of pediatric Hematology, Oncology, and Blood & Marrow Transplantation at the Children's Hospital Los Angeles (Los Angeles, CA). Dr. Orgel's clinical specialty focuses on higher risk and rare malignant hematology, and specifically, Mixed-Phenotype Acute Leukemia (MPAL). He possesses an academic appointment as an Associate Professor of Clinical Pediatrics in the Keck School of Medicine of the University of Southern California (USC) and earned a Masters of Science in Clinical and Biomedical Investigations from the Department of Preventive Medicine at USC.
Dr. Orgel's primary research interest lies in the field of medical supportive care or "cancer control" (reducing acute and late treatment-related toxicities). The goal of his translational research is to target specific toxic effects to widen therapeutic windows for common chemotherapies and/or improve the quality of life of children with cancer. Currently, Dr. Orgel's investigator- initiated research includes two primary areas of emphasis (1) studying new agents and novel strategies to reduce hearing loss from chemotherapy (cisplatin), and (2) targeting overweight and obesity in pediatric ALL to reduce chemoresistance and improve survival.